Skip to main content
NCBI home page
Brain Pathology logoLink to Brain Pathology
. 2008 Jan 28;7(2):723–730. doi: 10.1111/j.1750-3639.1997.tb01058.x

A Confocal Microscopic Analysis of Galaninergic Hyperinnervation of Cholinergic Basal Forebrain Neurons in Alzheimer's Disease

Robert Bowser 1, Jeffrey H Kordower 2, Elliott J Mufson 2,✉
PMCID: PMC8098448  PMID: 9161723

Abstract

The galanin (GAL) containing peptide fiber system innervates the basal forebrain and has been shown to hyperinnervate remaining cholinergic neurons in Alzheimer's disease (AD). GAL modulates the release of acetylcholine and, therefore, may depress this neurotransmitter in surviving cholinergic basal forebrain (CBF) neurons in AD. The aim of this study was to identify putative synaptic contacts between GAL immunoreactive processes and CBF neurons and evaluate whether these processes hypertrophy in AD patients. We observed by confocal laser microscopy a hyperinnervation of GAL‐containing fibers in both AD and Parkinson's disease patients with concurrent AD (PD/AD). Galaninergic fibers were often seen in direct apposition to remaining CBF neurons and enwrapped cholinergic cell soma and dendrites. Our results demonstrate that GAL‐containing fibers are in direct apposition to CBF neurons in normal‐aged humans and that this phenotype is enhanced in AD and PD/AD, suggesting that direct synaptic contacts occur between GAL‐containing fibers and CBF neurons. Because GAL can modulate acetylcholine release from cholinergic neurons, hyperinnervation of GAL fibers in AD and PD/AD patients may further decrease release of acetylcholine from remaining CBF neurons. We propose that therapies based solely on acetylcholinesterase inhibitors may be insufficient to effectively increase cortical levels of acetylcholine.

Full Text

The Full Text of this article is available as a PDF (4.7 MB).

References

  • 1. Bartus RT, Dean RL, Beer B., Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217: 408–417. [DOI] [PubMed] [Google Scholar]
  • 2. Benzing WC, Kordower JH, Mufson EJ (1993) Galanin immunoreactivity within the primate basal forebrain: Evolutionary change between monkeys and apes. J Comp Neurol 336: 31–39. [DOI] [PubMed] [Google Scholar]
  • 3. Brady DR, Mufson EJ (1991) Alz‐50 immunoreactive neuropil differentiates hippocampal complex subfields in Alzheimer's disease. J Comp Neurol 305: 489–507. [DOI] [PubMed] [Google Scholar]
  • 4. Chan‐Palay V. (1988) Galanin hyperinnervates surviving neurons of the human basal nucleus of meynert in dementias of Alzheimer's disease and Parkinson's disease: A hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia. J Comp Neurol 273: 543–557. [DOI] [PubMed] [Google Scholar]
  • 5. Chan‐Palay V. (1988) Neurons with galanin innervate cholinergic cells in the human basal forebrain and galanin and acetylcholine coexist. Brain Res 21: 465–472. [DOI] [PubMed] [Google Scholar]
  • 6. Chan‐Palay V., Ernfors P., Person H. (1990) Galanin gene expression in the nucleus basalis of meynert in senile dementia of the Alzheimer type. Dementia 1: 192–196. [Google Scholar]
  • 7. Chan‐Palay V., Jentsch B., Lang W., Hochli M., Asan E. (1990) Distribution of neuropeptide Y, C‐terminal flanking peptide of NPY and galanin and coexistence with catecholamine in the locus ceruleus of normal human, Alzheimer's dementia and Parkinson's disease brains. Dementia 1: 18–31. [Google Scholar]
  • 8. Crawley JM, Wenk GL (1989) Co‐existence cf galanin and acetylcholine: Is galanin involved in memory processes and dementia Trends Neurosci 12: 278–282. [DOI] [PubMed] [Google Scholar]
  • 9. Davies P., Maloney AJF (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2: 1403. [DOI] [PubMed] [Google Scholar]
  • 10. Dav's KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, Schneider LS, Whitehouse PJ, Hoover TM, Morris JC, Kawas CH, Knopman DS, Earl ML, Kumar V., Doody RS, Group TICS (1992) A double‐blind, placebo‐controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 327: 1253–1259. [DOI] [PubMed] [Google Scholar]
  • 11. Farlow M., Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan‐Ureno J., Group TTS (1992) A controlled trial of tacrine in Alzheimer's disease. JAMA 268: 2523–2529. [PubMed] [Google Scholar]
  • 12. Fisone G., Wu CF, Consolo S., Nordstrom O., Brynne N., Bartfai T., Melander T., Hokfelt T. (1987) Galanin inhibits acetylcholine release in the ventral hippocampus of the rat: Histochemical, autoradiographic, in vivo, and in vitro studies. Proc Natl Acad Sci USA 84: 7339–7343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Gabriel SM, Bierer LM, Davidson M., Purohit DP, Perl DP, Harotunian V. (1994) Galanin‐like immunoreactivity is increased In the postmortem cerebral cortex from patients with Alzheimer's disease. J Neurochem 62: 1516–1523. [DOI] [PubMed] [Google Scholar]
  • 14. Givers BS, Olton DS, Crawiey JN (1992) Galanin in the medial septal area impairs working memory. Brain Res 582: 71–77. [DOI] [PubMed] [Google Scholar]
  • 15. Henderson VW, Paganini‐Hill A., Emanuel CK, Dunn ME, Buckwalter JG (1994) Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 51: 896–900. [DOI] [PubMed] [Google Scholar]
  • 16. Henderson Z., Morris N. (1997) Galanin immunoreactive synaptic terminals on basal forebrain cholinergic neurons in the rat. J Comp Neurol (in press). [DOI] [PubMed]
  • 17. Ikeda M., Dewar D., McCulloch J. (1995) Galanin receptor binding sites in the temporal and occipital cortex are minimally affected in Alzheimer's disease. Neurosci Lett 192: 37–40. [DOI] [PubMed] [Google Scholar]
  • 18. Katzman R., Terry R., de Teresa R., Brown T., Davies P., Fuld P., Renbing X., Peck A. (1988) Clinical pathological and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 23: 138–144. [DOI] [PubMed] [Google Scholar]
  • 19. Khachaturian ZS, Pnelps CH, Buckholtz NS (1994) The prospect of developing treatments for Alzheimer disease. In: Alzheimer Disease, Terry RD, Katzman R., Bick KL (eds.), pp. 445–454, Raven Press, Ltd.: New York , NY , USA . [Google Scholar]
  • 20. Kirkpatrick JB, Hicks P. (1984) Nucleus basalls in Down's syndrome. J Neuropathol Exp Neurol 43: 307. [Google Scholar]
  • 21. Kohler C., Chan‐Palay V. (1990) Preservation of galanin receptors in the human basal nucleus of meynert in senile dementia of the Alzheimer type. Dementia 1: 82–89. [Google Scholar]
  • 22. Kordower JH, Gash DM, Bothwell MA, Hersh LB, Mufson EJ (1989) Nerve growth factor receptor and choline acetyltransferase remain colocalized in the nucleus basalis (Dh4) of Alzheimer's patients. Neurobiol Aging 10: 67–74. [DOI] [PubMed] [Google Scholar]
  • 23. Kordower JH, Le HK, Mufson EJ (1992) Galanin immunoreactivity in the primate central nervous system. J Comp Neurol 319: 479–500. [DOI] [PubMed] [Google Scholar]
  • 24. Kordower JH, Mufson EJ (1990) Galanin‐like immunoreactivity in the basal forebrain of monkeys and humans: Differential staining patterns between species. J Comp Neurol 294: 281–292. [DOI] [PubMed] [Google Scholar]
  • 25. McGeer PL, Rogers J. (1992) Anti‐infammatory agents as a therapeutic approach to Aizheimer's disease. Neurology 42: 447–448. [DOI] [PubMed] [Google Scholar]
  • 26. Melanaer T., Hökfelt F., Rökaeas A. (1986) Distribution of galaninlike immunoreactivity in the rat central nervous system. J Comp Neurol 248: 475–547. [DOI] [PubMed] [Google Scholar]
  • 27. Merchenthaler I., Lopez FJ, Negro‐Vilar A. (1993) Anatomy and physiology of central galanin‐containing pathways. Prog Neurobiol 40: 714–769. [DOI] [PubMed] [Google Scholar]
  • 28. Mesulam MM, Mufson EJ, Levey AI, Wainer BH (1983) Cholinergic innervation of cortex by the basal forebrain: Cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata) and hypothalamus in the rhesus monkey. J Comp Neurol 214: 170–197. [DOI] [PubMed] [Google Scholar]
  • 29. Mirra SS, Heyman A., McKee D. (1991) The Consortium to Establish a Registry for Aizheimer's Disease (CERAD). II. Standardization of the neuropathological assessment of Alzheimer's disease. Neurology 41: 479–486. [DOI] [PubMed] [Google Scholar]
  • 30. Mufson EJ, Bothwell M., Hersh LB, Kordower JH (1989) Nerve growth factor receptor‐immunoreactive profiles in the normal‐aged human basal forebrain: Colocalization with cholinergic enzymes. J Comp Neurol 285: 196–217. [DOI] [PubMed] [Google Scholar]
  • 31. Mufson EJ, Bothwell M., JH K. (1989) Loss of nerve growth factor receptor‐containing neurons in Alzheimer's disease: A quantitative analysis across subregions of the basal forebrain. Exp Neurol 105: 221–232. [DOI] [PubMed] [Google Scholar]
  • 32. Mufson EJ, Cochran E., Benzing W., Kordower JH (1993) Galaninergic innervation of the cholinergic vertical limb of the diagonal band (Ch2) and bed nucleus of the stria terminalis in aging, Alzheimer's disease and Down's syndrome. Dementia 4: 237–250. [DOI] [PubMed] [Google Scholar]
  • 33. Mufson EJ, Presley, LM J.H.K. (1991) Nerve growth factor receptor immunoreactivity within the nucleus basalis (Ch4) in Parkinson's disease: Reduced cell numbers and colocalization with cholinergic neurons. Brain Res 531: 19–30. [DOI] [PubMed] [Google Scholar]
  • 34. Ohkura T., Isse K., Akazawa K., Hamamoto M., Yaol Y., Hagino N. (1995) Long‐term estrogen replacement therapy in female patients with dementia of the Alzneimer type: 7 case reoorts. Dementia 6: 99–107. [DOI] [PubMed] [Google Scholar]
  • 35. Planas B., Kolb PE, Raskind MA, Miller MA (1996) Nerve growth factor induces galanin expression: in rat basal forebrain. Soc Neurosci Abstr 221–754. [PubMed]
  • 36. Rokaeus A., Brownstein MJ (1986) Construction of a porcine adrenal medullary cDNA library and nucleotide sequence analysis of two clones encoding a galanin precursor Proc Natl Acad Sci USA 83: 6287–6291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Shvaloff A., Neuman E., Guez D. (1996) Lines of therapeutics research in Alzheimer's disease. Psychopharmacol Bull 32: 343–352. [PubMed] [Google Scholar]
  • 38. Tatemoto K., Rokaeus A., Jornvail H., McDonala TJ, Mutt V. (1983) Galanin ‐ a novel biologically active peptide from porcine intesting. FEBS Lett 164: 124–128. [DOI] [PubMed] [Google Scholar]
  • 39. Walker LC, Rance NE, Price DL, Young WS (1991) Galanin mRNA in the nucleus basalis of meynert complex of baboons and human. J Comp Neurol 303: 113–120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Whitehouse PJ, Price DL, Struble RG (1982) Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 215: 1237–1239. [DOI] [PubMed] [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES